Navigation Links
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Date:10/27/2011

ROCKVILLE, Md., Oct  27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed Phase Ia in the ongoing safety trial to test its neuroregenerative small molecule drug, NSI-189, in the treatment of major depressive disorder (MDD).  Phase Ia tested the drug in healthy volunteers for safety and tolerability. Phase Ib, which the company expects to commence later this year, will test the safety and tolerability of NSI-189 in depressed patients.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD and other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).

"We are extremely pleased the trial has progressed so smoothly," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "We didn't see any drug-related adverse effects in this set of patients. We are eager to move to the next phase of this safety trial, where we will be testing NSI-189 in patients who suffer from major depressive disorder."

About the Trial

This Phase Ia trial tested single ascending doses of NSI-189 in healthy patients. Standard safety endpoints were monitored.  All doses were well tolerated and there were no drug-related serious adverse events.  The trial will commence to the Ib phase, testing the safety of escalating doses of daily administration for 28 days in depressed patients. The entire Phase I trial is expected to be approximately one year in duration.

About NSI-189

NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Lincor Inc. ... patient experience technology to New Jersey ... five-year agreement, CarePoint Health will deploy Lincor,s PatientLINC ... Center, Christ Hospital and Hoboken University Medical Center. ... range of software solutions to help hospitals reach ...
(Date:8/19/2014)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW Bio), ... solid tumor cancers, announced today that the $17.5 million ... has closed.  The three-year notes have a 5% interest ... common stock.  The investors also have an option, exercisable ... 30% of these notes on the same terms. ...
(Date:8/19/2014)... 2014 Research and Markets has ... - Global Strategic Business Report" report to their ... markets for Pharmaceutical Contract Manufacturing in US$ Thousand by ... solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid ... Ointments). The report provides separate comprehensive analytics ...
Breaking Medicine Technology:Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
(Date:8/20/2014)... The non-small cell lung cancer (NSCLC) market value ... the top 8 developed nations, from just over USD ... billion by 2020-end, posting a CAGR of 6.6% during ... driven by innovative therapies entering the squamous cell carcinoma ... the non-squamous segment. Thus, patients with SCC are expected ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the ... company in recent years, developing or acquiring 2 million ... including more than $100 million last year alone. , ... new geographic regions and a wider array of product ... announce an enhanced brand identity that includes a new ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... The award-winning plastic surgery group, The Aesthetic Center ... Houston to a third office, located in Katy, Texas ... ACPS plastic surgeon Dr. Rolando Morales said the expansion ... risen to become one of the largest, most respected ... its establishment in 1996 by plastic surgeons Dr. Christopher ...
Breaking Medicine News(10 mins):Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2
... Vision ... Expand Access to Care, WASHINGTON, April 9, 2008 ... health care,policy issues by doctors of optometry from his district ... in West Virginia and the AOA are working to pass ...
... 9 Nu Skin Enterprises,Inc. (NYSE: NUS ) ... the market opening on Thursday, May 1, 2008., ... a,conference call with the investment community later that same ... can expect to hear,management review past results and discuss ...
... housework, is good for mental health , , WEDNESDAY, April 9 (HealthDay ... clean your house and boost your mood. , In ... activity a week helped mental health, although the more vigorous the ... published online Thursday in the British Journal of Sports Medicine ...
... 9 The following statement,was issued today by William ... York,s leaders have taken historic action to protect the ... use by increasing,the state cigarette tax by $1.25 to ... tax increase ever enacted and gives New York the,highest ...
... One month of tough breathing may help asthma sufferers breathe ... University of Houston professor. , In a move ... Hippocratic Oath first do no harm Richard Bond, ... long-standing medical taboo to treat asthma. Although counterintuitive, Bonds ...
... may also identify children at risk , , WEDNESDAY, April ... responsible for cardiac hypertrophy (thickening of the heart muscle) ... this rare but life-threatening condition in children, says a ... children who had no family history of the condition, ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Whisk Those Blues Away 2Health News:New York Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Gene Mutations for Rare Heart Disease Also Found in Kids 2
Sedillot periosteal elevator, 16 mm, sharp, 7"....
Periosteal elevator #9H, 17.5 cm, 7"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... The Anterior Isola System is ... scoliotic, lordotic or kyphotic spinal ... stiff fixation bridge parallel to ... spine. The system, developed for ...
Medicine Products: